摘要
在过去的三十年里广泛的研究已经表明,代谢型谷氨酸(mGlu)受体在中枢神经系统(CNS)主要功能中有重要作用。很多的临床前研究提供的证据表明,代谢型谷氨酸受体的靶向药物能有效减轻动物模型中的症状发展和许多中枢神经系统疾病的进展。本综述总结了在病理生理学神经精神疾病(精神分裂症、抑郁症、焦虑症和认知障碍,疼痛的感知和上瘾)参与代谢型谷氨酸受体的当前知识,包括神经退行性疾病(老年痴呆症,阿尔茨海默氏病和帕金森病)和神经发育(脆性X综合症和自闭症谱系障碍)疾病。我们进一步强调治疗在这些疾病中代谢型谷氨酸受体的药理调节潜力,用这些化合物描述临床试验的结果和讨论转化困难的潜在来源。
关键词: 自闭症,脆性X综合症,精神障碍,代谢型谷氨酸受体,神经退行性疾病,疼痛。
Current Drug Targets
Title:Metabotropic Glutamate Receptors in Central Nervous System Diseases
Volume: 17 Issue: 5
Author(s): Anna V. Golubeva, Rachel D. Moloney, Richard M. O’Connor, Timothy G. Dinan and John F. Cryan
Affiliation:
关键词: 自闭症,脆性X综合症,精神障碍,代谢型谷氨酸受体,神经退行性疾病,疼痛。
摘要: Extensive research over the past thirty years has demonstrated a vital role for metabotropic glutamate (mGlu) receptors in the major functions of the central nervous system (CNS). A wealth of preclinical studies provide evidence that pharmacological targeting of mGlu receptors can effectively attenuate the development of symptoms and progression of many CNS disorders in animal models. In this review we summarize the current knowledge on the involvement of mGlu receptors in the pathophysiology of neuropsychiatric disorders (schizophrenia, depression, anxiety and cognitive disorders, pain perception and addiction), as well as neurodegenerative (Alzheimer’s, Huntington’s and Parkinson’s diseases) and neurodevelopmental (fragile X syndrome and autism spectrum disorders) diseases. We further emphasize the therapeutic potential of mGlu receptors’ pharmacological modulators in these diseases, describe the results of clinical trials with these compounds and discuss the potential sources of translational difficulties.
Export Options
About this article
Cite this article as:
Anna V. Golubeva, Rachel D. Moloney, Richard M. O’Connor, Timothy G. Dinan and John F. Cryan , Metabotropic Glutamate Receptors in Central Nervous System Diseases, Current Drug Targets 2016; 17 (5) . https://dx.doi.org/10.2174/1389450116666150316224011
DOI https://dx.doi.org/10.2174/1389450116666150316224011 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Developments in Targeting Bromodomain and Extra Terminal
Domain Proteins for Cancer Therapeutics
Current Medicinal Chemistry Encapsulation of Imatinib in Targeted KIT-5 Nanoparticles for Reducing its Cardiotoxicity and Hepatotoxicity
Anti-Cancer Agents in Medicinal Chemistry Discovery of Small Molecule c-Met Inhibitors: Evolution and Profiles of Clinical Candidates
Anti-Cancer Agents in Medicinal Chemistry Safety of Multi-Targeted Kinase Inhibitors as Monotherapy Treatment of Cancer: A Systematic Review of the Literature
Current Drug Safety Shutting Down the Furnace: Preferential Killing of Cancer Cells with Mitochondrial-Targeting Molecules
Current Medicinal Chemistry The Dual Role of Tumor Necrosis Factor (TNF) in Cancer Biology
Current Medicinal Chemistry Human Sirtuins: An Overview of an Emerging Drug Target in Age-Related Diseases and Cancer
Current Drug Targets Anti-EGFR-mAb and 5-Fluorouracil Conjugated Polymeric Nanoparticles for Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery ZD6474, a Small Molecule Tyrosine Kinase Inhibitor, Potentiates the Anti-Tumor and Anti-Metastasis Effects of Radiation for Human Nasopharyngeal Carcinoma
Current Cancer Drug Targets Neovascular Age-related Macular Degeneration: Past, Present, and Future
Current Angiogenesis (Discontinued) Angiogenesis as a Therapeutic Target in Arthritis: Lessons from Oncology
Current Pharmaceutical Design Glycogen Synthase Kinase-β3 in Ischemic Neuronal Death
Current Neurovascular Research The Effect of Chemotherapy/Radiotherapy on Cancerous Pattern Recognition by NK Cells
Current Medicinal Chemistry Methionine-Derived Metabolites in Apoptosis: Therapeutic Opportunities for Inhibitors of their Metabolism in Chemoresistant Cancer Cells
Current Medicinal Chemistry In vivo Evaluation and Alzheimer’s Disease Treatment Outcome of siRNA Loaded Dual Targeting Drug Delivery System
Current Pharmaceutical Biotechnology T11TS/SLFA-3 Differentially Regulate the Population of Microglia and Brain Infiltrating Lymphocytes to Reduce Glioma by Modulating Intrinsic Bcl-2 Expression rather than p53
Central Nervous System Agents in Medicinal Chemistry Nitroimidazole Radiopharmaceuticals in Bioimaging: Part I: Synthesis and Imaging Applications
Current Radiopharmaceuticals A QSAR Study on Novel Series of Carbonic Anhydrase Inhibitors hCA IX—Tumor-Associated (Hypoxia)
Medicinal Chemistry Macrophage Derived Cystatin B/Cathepsin B in HIV Replication and Neuropathogenesis
Current HIV Research Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued)